Research conducted at the Angiogenesis Laboratory at Massachusetts Eye and Ear Infirmary, has for the first time, identified the mode of death of cone photoreceptor cells in an animal model of retinitis pigmentosa (RP).
[More]
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.
[More]
Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.
[More]
BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.
[More]
A team of University of California, Berkeley, scientists in collaboration with researchers at the University of Munich and University of Washington in Seattle has discovered a chemical that temporarily restores some vision to blind mice, and is working on an improved compound that may someday allow people with degenerative blindness to see again.
[More]
Oxford BioMedica plc, the leading gene-based biopharmaceutical company, today announces that the US non-profit organisation, the Foundation Fighting Blindness (FFB), has granted an award of US$125,000 to the Company via its translational research arm, the Foundation Fighting Blindness Clinical Research Institute (FFBCRI) formerly known as the National Neurovision Research Institute (NNRI).
[More]
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced positive results from formal studies of its BDM-E eye disease drug, presented over 21 – 22 July at the International Society for Eye Research (ISER) meeting in Berlin, Germany. The ISER convenes leading researchers and clinicians in the area of eye disease.
[More]
Second Sight Medical Products Inc., the world's leading developer and manufacturer of retinal prostheses, today announced that a U.S. Food and Drug Administration (FDA) Ophthalmic Devices Advisory Panel has been scheduled to review the data presented in the company's Humanitarian Device Exemption (HDE) market approval application for its Argus II Retinal Prosthesis System (Argus II prosthesis) on September 28, 2012 in Gaithersburg, Maryland.
[More]
Research to Prevent Blindness (RPB) has awarded a grant of $110,000 to the Massachusetts Eye and Ear Infirmary to support research into the causes, treatment and prevention of blinding diseases. The research will be directed by Joan W. Miller, M.D., Chief of the Mass. Eye and Ear and Mass. General Hospital's Departments of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School.
[More]
Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.
[More]
Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell Services.
[More]
The Foundation Fighting Blindness and Massachusetts Eye and Ear will host the Optogenetic Therapies for Vision workshop on Friday, June 1, from 8 a.m.-6 p.m., in Boston.
[More]
Using tiny solar-panel-like cells surgically placed underneath the retina, scientists at the Stanford University School of Medicine have devised a system that may someday restore sight to people who have lost vision because of certain types of degenerative eye diseases.
[More]
Gene therapy strategies to prevent and treat inherited diseases of the retina that can cause blindness have progressed rapidly. Positive results in animal models of human retinal disease continue to emerge, as reported in several articles published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
[More]
The same technology used by astronomers to obtain clear views of distant stars is now being used by optometrists to perform incredibly detailed examinations of the living eye.
[More]
In a medical breakthrough two blind men have regained partial sight for the first time in more than 20 years after receiving a “bionic eye”. Scientists said the first clinical trials of the microchip eye implant, which measures just 3mm across and is fitted behind the eyeball, have proved successful and “exceeded expectations”.
[More]
The University College London researchers transplanted immature vision cells directly into the mouse retina. They noted that within weeks the cells began to integrate into the retina and the researchers, led by Prof Robin Ali in the university’s Institute of Ophthalmology, were able to show that vision began to return to the mice.
[More]
New research finds that omega-3 polyunsaturated fatty acids (PUFAs) found in seafood (long-chain omega-3s) may reduce the risk of precancerous colorectal polyps in women, enhance the muscular benefits of strength training in older women and improve eye health after corneal surgery.
[More]
For the first time, scientists at the University of Wisconsin-Madison have made early retina structures containing proliferating neuroretinal progenitor cells using induced pluripotent stem (iPS) cells derived from human blood.
[More]
A newly developed, genetically modified pig may hold the keys to the development of improved treatments and possibly even a cure for retinitis pigmentosa (RP), the most common inherited retinal disease in the United States.
[More]